The psychological impact of therapeutic changes during the COVID-19-lockdown for gynaecological and breast cancer patients
COVID-19 pandemic
Gynaecological cancer
Psychological symptoms
SARS-CoV-2
breast cancer
Journal
Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
13
10
2021
revised:
22
12
2021
accepted:
05
01
2022
pubmed:
11
1
2022
medline:
25
2
2022
entrez:
10
1
2022
Statut:
ppublish
Résumé
The exceptional health situation related to the Coronavirus 2019 (COVID-19) pandemic has required an in-depth and immediate reorganisation of gynaecological cancer care. The main objective was to assess the psychological impact of such treatment modifications during the lockdown period for gynaecological and breast cancer patients. A multicentre prospective study was conducted in three university gynaecological cancer wards (Hospices Civils de Lyon, France) during the French first lockdown (16th March to 11th May 2020). All patients with non-metastatic breast cancer or gynaecological cancer were included. Data was collected regarding treatment modifications (delay, cancellation, change of therapeutic plan). The psychological impact of treatment modifications during and after the lockdown was assessed by validated questionnaires (SF-12, EORTC-QLQ-C30, HADS). A total of 205 consecutive patients were included, aged 60.5 ± 1.0 years. Seven patients (3.4%) presented a SARS-CoV-2 infection, and two patients died. Treatment was maintained for 122 (59.5%) patients, postponed for 72 (35.1%) and cancelled for 11 (5.4%). During the lockdown, 35/118 (29.7%) patients suffered from confirmed anxiety and the mean fatigue-EORTC score was 48.00 ± 2.51; it was 38.64 ± 2.33 (p = 0.02) after the lockdown. After the lockdown and compared to the lockdown period, the mental SF-12 score and overall health status EORTC score were significantly higher (45.03 ± 1.06 vs 41.71 ± 1.15, p = 0.02 and 64.58 ± 1.66 vs 57.44 ± 2.02, p = 0.0007, respectively). The number of confirmed-anxiety cases was significantly higher amongst patients for whom treatment was delayed or cancelled (40.5% vs 23.7%, p = 0.04). This study quantified the treatment modifications of gynaecological cancer patients during the COVID-19 lockdown and revealed a poorer psychological state and quality of life during this period, even for patients whose treatment plan was not actually modified. Anxiety was more significant in patients with a delayed or cancelled treatment.
Identifiants
pubmed: 35007776
pii: S2468-7847(22)00003-4
doi: 10.1016/j.jogoh.2022.102311
pmc: PMC8739811
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
102311Informations de copyright
Copyright © 2022 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.
Références
Cancer Med. 2021 Jan;10(1):208-219
pubmed: 33205595
Cancer. 2020 Oct 1;126(19):4414-4422
pubmed: 32697342
PLoS One. 2020 Oct 30;15(10):e0241741
pubmed: 33125442
Prev Med. 2021 Oct;151:106585
pubmed: 34217412
Eur J Cancer. 2020 Sep;136:132-139
pubmed: 32683273
Curr Oncol. 2021 Jan 08;28(1):294-300
pubmed: 33430131
Infect Dis (Lond). 2019 Jul;51(7):502-509
pubmed: 31081422
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):779-788
pubmed: 32526627
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Cancer Med. 2021 Jun;10(12):3928-3937
pubmed: 33973411
Psychol Med. 2021 Jan;51(2):201-211
pubmed: 33436130
Gynecol Obstet Fertil Senol. 2020 Nov;48(11):777-783
pubmed: 33010487
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
In Vivo. 2021 Jan-Feb;35(1):663-670
pubmed: 33402524
JCO Glob Oncol. 2020 Oct;6:1494-1509
pubmed: 33017179
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Front Psychol. 2020 Aug 24;11:2033
pubmed: 32982846
Br J Surg. 2020 Jun;107(7):785-787
pubmed: 32191340
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Bull Cancer. 2020 May;107(5):528-537
pubmed: 32278467
Am J Obstet Gynecol. 2020 Nov;223(5):725.e1-725.e9
pubmed: 32598911
Encephale. 2020 Jun;46(3):193-201
pubmed: 32370982
J Gynecol Obstet Hum Reprod. 2020 Jun;49(6):101729
pubmed: 32247066
Health Place. 2020 Nov;66:102440
pubmed: 32947185
Int J Environ Res Public Health. 2020 Mar 06;17(5):
pubmed: 32155789
J Affect Disord. 2021 Jul 1;290:364-377
pubmed: 34052584
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Front Oncol. 2020 Jul 10;10:1270
pubmed: 32754447